Iovance Biotherapeutics (IOVA) Asset Utilization Ratio (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Asset Utilization Ratio of 0.31 for Q1 2026, up 37.09% year-over-year from 0.23 in Q1 2025, and up 7.17% quarter-over-quarter from 0.29 in Q4 2025.
Iovance Biotherapeutics (IOVA) Asset Utilization Ratio (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Asset Utilization Ratio for 4 consecutive years, with 0.31 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 37.09% year-over-year to 0.31; the TTM figure through Mar 2026 stood at 0.31 (up 37.09% YoY), while the FY2025 annual figure was 0.29, up 48.91% from the prior year.
- Asset Utilization Ratio grew to 0.31 in Q1 2026 per IOVA's latest filing, from 0.29 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.31 in Q1 2026 and bottomed at 0.0 in Q2 2023.
- Historically, Asset Utilization Ratio has averaged 0.15 across 4 years, with a median of 0.23 in 2025.
- Annual changes were most pronounced in 2025 — Asset Utilization Ratio surged 9719.44% — and 2026, when it surged 37.09%.
- Iovance Biotherapeutics' Asset Utilization Ratio stood at 0.0 in 2023, then jumped by 58.43% to 0.0 in 2024, then soared by 12461.07% to 0.29 in 2025, then increased by 7.17% to 0.31 in 2026.
- Business Quant data shows IOVA's Asset Utilization Ratio at 0.31 in Q1 2026, 0.29 in Q4 2025, and 0.28 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 0.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.35 |
| Mar 31, 2026 | 0.31 |
| Dec 31, 2025 | 0.29 |
| Sep 30, 2025 | 0.28 |
| Jun 30, 2025 | 0.26 |
| Mar 31, 2025 | 0.23 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |